Form 4: UNH CFO Wayne DeVeydt Granted Equity Awards

UnitedHealth Group's Chief Financial Officer, Wayne S. DeVeydt, was granted 10,525 restricted stock units and 42,551 non-qualified stock options as part of his compensation.

Summary

• Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group Inc. (UNH), was granted equity awards on September 2, 2025.
• The awards include 10,525 shares of Common Stock, which are restricted stock units (RSUs), acquired at a price of $0.
• Additionally, 42,551 non-qualified stock options were granted with an exercise price of $308.8, also acquired at a price of $0.
• Both the RSUs and stock options vest at a rate of 25% annually on September 2, from 2026 through 2029.
• The non-qualified stock options have an expiration date of September 2, 2035.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event, indicating stability in management incentives and a commitment to long-term value creation. It's a neutral to slightly positive signal as it aligns executive interests with shareholders.

Positives

• The grant of equity awards aligns the Chief Financial Officer's long-term financial interests with those of shareholders, promoting value creation.
• The multi-year vesting schedule (25% annually over four years) serves as a strong incentive for the retention of a key executive.

Negatives

• No immediate cash benefit for the executive, as the awards are subject to future vesting conditions.

Risks

• The ultimate value realized from the stock options and restricted stock units is dependent on the future performance of UnitedHealth Group's stock price.
• Vesting conditions require continued employment, posing a risk to the executive if employment ceases before the full vesting schedule is completed.

Future Outlook

The vesting schedule for the equity awards extends through September 2029, indicating a long-term incentive structure designed to retain the Chief Financial Officer and align his performance with the company's sustained growth. The stock options have an extended expiration date of September 2035, providing a long window for potential exercise based on future stock performance.

Industry Context

Executive equity grants are a standard and widely adopted component of compensation packages for senior management in large, publicly traded companies across all sectors, including the healthcare industry. These grants are strategically designed to align executive incentives with long-term shareholder value creation and to ensure the retention of key talent.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) and non-qualified stock options is a common practice for executive compensation in the healthcare and broader corporate sectors.
• A multi-year vesting schedule (25% annually over four years) is typical for such awards, similar to practices at peer companies like CVS Health (CVS) or Elevance Health (ELV), which also use long-term equity incentives to retain key talent and motivate performance.
• The exercise price of $308.8 for the options would be compared to the market price of UNH stock on the grant date to assess its 'in-the-money' or 'out-of-the-money' status, a standard evaluation for option grants.

Related Party Transactions

• The grant of equity awards to Wayne S. DeVeydt, the Chief Financial Officer, by UnitedHealth Group Inc. constitutes a related party transaction, as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The equity grant aligns the CFO's long-term financial interests with shareholder value creation, potentially leading to more focused strategic decisions and sustained performance.
• Employees: Standard executive compensation practices can set a precedent for other employee incentive programs, influencing overall compensation philosophy.
• Management: Provides long-term incentives and retention for a key executive, ensuring continuity in leadership and strategic execution.

Next Steps

• The restricted stock units and non-qualified stock options will vest annually on September 2 from 2026 through 2029.
• The non-qualified stock options can be exercised until their expiration date of September 2, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (equity grant) and does not contain information that would fundamentally alter the investment thesis for UnitedHealth Group. It reinforces the alignment of executive incentives with long-term shareholder value but does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

UnitedHealth Group, UNH, Wayne S. DeVeydt, CFO, Form 4, SEC filing, equity grant, restricted stock units, stock options, insider transaction, executive compensation, 10b5-1 plan